ENGOT Early Drug Development Group

Mission Statement

• We aim to accelerate the development of new therapies derived from a solid scientific rational for women with gynaecological cancer through European collaboration.

• We aim at using the multidisciplinary expertise available within ENGOT to develop therapies via full spectrum clinical testing from first in human trials to randomised registration trials.

• We aim at strengthening the scientific basis for late stage clinical testing through early clinical testing with strong integrated translational research.

Objectives

• To develop a network of early phase trial centres and investigators within ENGOT to deliver early phase clinical trials with strong scientific rational.

• To develop novel trial designs that allow efficient assessment of new compounds and make it feasible to also investigate rare histological and molecular subtypes.

• To offer pharmaceutical companies a read-to-go, efficient structure and academic expertise for accelerated clinical development of their compounds in their pipeline

• To deliver the most promising new compounds and therapeutic approaches to women with gynaecological cancer.

Working Group Chairs

For contact details of the Chairs, please reach out to ENGOT Office at engot@esgo.org. Elections for the next Chair-Elects will take place in 2027.